Steven Almany
Cardiovascular Disease · Troy, MINPI 1295717205
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $466,500 of the $470,508 with a category attached, or 99.1%. Corindus Inc. accounts for 99.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $469,293 and has fallen 99.9% since, to $368 in 2021. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $4356.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corindus Inc.$467K
- Siemens Medical Solutions USA, Inc.$1K
- Edwards Lifesciences$546
- Medtronic$421
- Novartis$317
- Sanofi-aventis U.S. LLC$266
- plus $990 from 17 others
Across 19 payments — averaging $625.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$9K
- Biotronik Inc.$3K
Across 13 payments — averaging $1006.68 each. An ownership or investment interest held by the physician or an immediate family member.
- Viseon, Inc.$13K
- Ablative Solutions, Inc.$0
What the payments were for
- Consulting fees$1,2500%
- Travel & lodging$120%
- Food & beverage$2,7461%
- Ownership interest$466,50099%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corindus Inc. | 2 | $466,619 |
| Siemens Medical Solutions USA, Inc. | 2 | $1,349 |
| Edwards Lifesciences | 8 | $546 |
| Medtronic(2 entities) | 4 | $421 |
| Novartis | 23 | $317 |
| Sanofi-aventis U.S. LLC | 5 | $266 |
| Johnson & Johnson | 23 | $219 |
| Amgen | 10 | $144 |
| Trice Medical, Inc. | 1 | $133 |
| Ablative Solutions, Inc. | 1 | $87 |
| Boston Scientific | 4 | $56 |
| Alnylam Pharmaceuticals Inc. | 4 | $54 |
| AstraZeneca | 4 | $46 |
| Amarin Pharma, Inc. | 3 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $44 |
| Boehringer Ingelheim | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Pfizer | 2 | $22 |
| Abbott | 1 | $20 |
| Preventice Services, LLC | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
| ZOLL Circulation Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$470,508 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Troy
- Michael GallagherTroy$284K
- Terry BowersTroy$255K
- Steven AjluniTroy$55K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.